Ginkgo Bioworks Q2 revenue falls 48% to $20 million as loss widens
Ginkgo Bioworks reported second quarter 2026 results on August 5, 2026. Revenue fell 48% to $20 million from $39 million, which the company attributed mainly to program rationalization tied to its restructuring, while its net loss from continuing operations and its Adjusted EBITDA loss both widened. Shareholders face a shrinking revenue base and larger losses, although the company reaffirmed its 2026 cash burn guidance.
Key points
- Second quarter revenue of $20 million, compared with $39 million a year earlier, a decrease of 48%
- Net loss from continuing operations of $57 million, compared with $53 million a year earlier
- Adjusted EBITDA loss of $36 million, compared with $25 million a year earlier
- Cash, cash equivalents and marketable securities of $302 million at June 30, 2026; full-year 2026 cash burn guidance of $125 million to $150 million reaffirmed
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 05, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.